Crescent Biopharma (NASDAQ:CBIO – Get Free Report) and Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.
Insider and Institutional Ownership
75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 66.0% of Lyell Immunopharma shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Crescent Biopharma and Lyell Immunopharma”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crescent Biopharma | $10.84 million | 43.50 | -$153.94 million | ($6.72) | -1.89 |
| Lyell Immunopharma | $40,000.00 | 5,620.30 | -$274.45 million | ($12.83) | -0.72 |
Crescent Biopharma has higher revenue and earnings than Lyell Immunopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Crescent Biopharma and Lyell Immunopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crescent Biopharma | N/A | -101.50% | -86.86% |
| Lyell Immunopharma | -920,285.25% | -91.62% | -70.50% |
Volatility and Risk
Crescent Biopharma has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings for Crescent Biopharma and Lyell Immunopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crescent Biopharma | 1 | 0 | 4 | 2 | 3.00 |
| Lyell Immunopharma | 1 | 1 | 6 | 1 | 2.78 |
Crescent Biopharma currently has a consensus price target of $33.00, suggesting a potential upside of 159.94%. Lyell Immunopharma has a consensus price target of $40.86, suggesting a potential upside of 345.26%. Given Lyell Immunopharma’s higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Crescent Biopharma.
Summary
Crescent Biopharma beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks.
About Crescent Biopharma
Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
About Lyell Immunopharma
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Crescent Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crescent Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
